These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2793021)

  • 1. [HIV antibody reaction caused by poliovirus].
    Fortschr Med; 1989 Jul; 107(22):12-3. PubMed ID: 2793021
    [No Abstract]   [Full Text] [Related]  

  • 2. [AIDS vaccines: an enigma in vaccine development].
    Dorner F; Barrett N
    Wien Klin Wochenschr; 1990 Jan; 102(2):51-8. PubMed ID: 1689919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV vaccine design and the neutralizing antibody problem.
    Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
    Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
    Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
    Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS vaccine.
    Minn Med; 1991 Mar; 74(3):46. PubMed ID: 2030681
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 12. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees.
    Rovinski B; Dekaban GA; Cao SX; Yao FL; Persson R; Matthews TJ; Klein MH
    Virology; 1999 May; 257(2):438-48. PubMed ID: 10329554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunization against HIV. Problems in developing a vaccine].
    Uhl D
    Med Monatsschr Pharm; 1988 Nov; 11(11):376-8. PubMed ID: 3059163
    [No Abstract]   [Full Text] [Related]  

  • 15. A recombinant immunodot assay for determination of HIV-1 GP41 antibody titres.
    Horváthová M; Struhárik M; Mayer V
    Acta Virol; 1992 Mar; 36(2):223. PubMed ID: 1359775
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
    J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disappointing data scuttle plans for large-scale AIDS vaccine trial.
    Cohen J
    Science; 2002 Mar; 295(5560):1616-7. PubMed ID: 11872804
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.